Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

University of Alberta

$688,500.00

Dietary ethanolamine and phosphoethanolamine phospholyase (ETNPPL) as novel modulators of liver health

EF 2021-22

Résumé
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25%, which means that over 8 million Canadians suffer from this disease. Increased understanding of the development and progression of NAFLD is crucially important for the development of novel therapies. We have identified the enzyme phosphoethanolamine phospholyase (ETNPPL) as a novel player in the development of liver disease. ETNPPL is reduced in patients with liver cancer. We have shown that mice with low expression of ETNPPL have higher fat in their liver. The goal of this project is to understand the physiological function of ETNPPL and how it interacts with the diet ethanolamine to influence liver health.
Programme
Project Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
443085
Name
Jacobs Rene L
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Nutrition, Food & Health
Projecttitle
Dietary ethanolamine and phosphoethanolamine phospholyase (ETNPPL) as novel modulators of liver health
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$688,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Diet-Gene Interaction; Lipids; Liver; Nutrition
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25%, which means that over 8 million Canadians suffer from this disease. Increased understanding of the development and progression of NAFLD is crucially important for the development of novel therapies. We have identified the enzyme phosphoethanolamine phospholyase (ETNPPL) as a novel player in the development of liver disease. ETNPPL is reduced in patients with liver cancer. We have shown that mice with low expression of ETNPPL have higher fat in their liver. The goal of this project is to understand the physiological function of ETNPPL and how it interacts with the diet ethanolamine to influence liver health.
Competitiondate
202104
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Jacobs, Rene L
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $688,500~ $0~